Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck
- PMID: 18391623
- DOI: 10.1097/CCO.0b013e3282f9b575
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck
Abstract
Purpose of review: The present study reviews recent developments of molecular-targeted therapies in the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma. It also highlights ongoing research regarding predictive markers of sensitivity or resistance to anti-epidermal growth factor receptor agents and discusses some promising novel targets in head and neck squamous cell carcinoma, as well as clinical trial design challenges.
Recent findings: Phase III randomized studies have brought the proof that cetuximab, an anti-epidermal growth factor receptor agent, is able to improve survival, either in combination with radiation therapy or in first-line treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. In addition, promising results have been obtained with antiangiogenic therapies in phase II trials. Some clinical and molecular markers of resistance to anti-epidermal growth factor receptor agents have been identified, but they have not yet been validated for clinical practice. Other interesting targets, such as insulin-like growth factor 1R or the PI3K/AKT/mTOR pathway, have been shown in vitro to play key roles in head and neck squamous cell carcinoma, and their inhibition warrants further evaluations.
Summary: Proof of the concept that molecular-targeted therapy is a valid therapeutic approach for head and neck squamous cell carcinoma has emerged with anti-epidermal growth factor receptor agents. Nevertheless, identification of predictive biomarkers of resistance or sensitivity to these therapies remains the main challenge in the optimal selection of patients most likely to benefit from them.
Similar articles
-
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.J Clin Oncol. 2006 Jun 10;24(17):2659-65. doi: 10.1200/JCO.2005.05.4577. J Clin Oncol. 2006. PMID: 16763280 Review.
-
New advances in targeted therapies for squamous cell carcinoma of the head and neck.Anticancer Drugs. 2011 Aug;22(7):626-33. doi: 10.1097/CAD.0b013e328341071e. Anticancer Drugs. 2011. PMID: 21048493 Review.
-
Molecular-targeted therapies in head and neck cancer.Semin Radiat Oncol. 2012 Jul;22(3):207-13. doi: 10.1016/j.semradonc.2012.03.005. Semin Radiat Oncol. 2012. PMID: 22687945
-
Emerging molecular targeted therapies in the treatment of head and neck cancer.Expert Opin Emerg Drugs. 2009 Jun;14(2):299-310. doi: 10.1517/14728210902997947. Expert Opin Emerg Drugs. 2009. PMID: 19519286 Review.
-
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.Expert Rev Anticancer Ther. 2009 Oct;9(10):1421-8. doi: 10.1586/era.09.113. Expert Rev Anticancer Ther. 2009. PMID: 19828002
Cited by
-
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.Cancer Discov. 2013 Jul;3(7):770-81. doi: 10.1158/2159-8290.CD-12-0537. Epub 2013 Apr 25. Cancer Discov. 2013. PMID: 23619168 Free PMC article.
-
Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy.PLoS One. 2015 Jul 24;10(7):e0133735. doi: 10.1371/journal.pone.0133735. eCollection 2015. PLoS One. 2015. PMID: 26208303 Free PMC article.
-
Clear cell sarcoma of the pancreas: a case report and review of literature.Int J Clin Exp Pathol. 2015 Feb 1;8(2):2171-5. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25973121 Free PMC article. Review.
-
[Cutaneous side effects of targeted cancer drugs].Hautarzt. 2017 Jan;68(1):12-18. doi: 10.1007/s00105-016-3902-3. Hautarzt. 2017. PMID: 27885401 Review. German.
-
Current aspects of targeted therapy in head and neck tumors.Eur Arch Otorhinolaryngol. 2008 Jul;265 Suppl 1:S3-12. doi: 10.1007/s00405-008-0697-6. Eur Arch Otorhinolaryngol. 2008. PMID: 18535834 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous